arrow
Y

Yasuhiko Nishioka

Tokushima University
H指数:51
被引数:9,560

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The providing multidisciplinary ILD diagnoses (PROMISE) study – study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis

提供多学科ILD诊断(PROMISE)研究——日本国家注册研究的设计,促进互动式在线多学科讨论诊断

2026-04-060
OAAI
Targeting Driver Mutations in Lung Cancer with Interstitial Pneumonia: A Nationwide Study in Japan

靶向伴有间质性肺炎的肺癌驱动突变:一项日本全国性研究

2026-01-120
PRE
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations

EGFR激活突变阳性的非小细胞肺癌患者在接受EGFR酪氨酸激酶抑制剂治疗期间化疗的生物学影响

2025-09-160
OAAI
Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation

时钟通路抑制剂通过调节纤维细胞分化克服肿瘤免疫排除

2025-08-050
OAAI
Diffuse pulmonary ossification and its association with cicatricial organising pneumonia in idiopathic and secondary forms
2025-04-110
OAAI
Effect of telomere length and TERT/TERC rare variants on survival in Japanese patients with idiopathic interstitial pneumonias :Genetic predisposition study from the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry (NEJ036A)
2024-10-300
PRE
Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study.
2023-10-271
PRE
Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8

IL-32β 和IL-32γ 同工型在调节恶性胸膜间皮瘤细胞生长以及vegf-a和CXCL8产生中的多样化和不同功能

2023-01-010
OAAI
Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression
2022-12-010
PRE
Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype
2022-09-266
OAAI
Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer
2022-08-012
OAAI
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial
2021-10-0110
OAAI